SynthesisFrontiers in pharmacology2025
Protective effects of salvianolic acid A on ischemic stroke: A meta-analysis of preclinical studies.
Synthesis in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The aim of this study was to investigate the protective effects of salvianolic acid A (SalA) on cerebral ischemic injury following ischemic stroke (IS) and its possible mechanisms, providing a scientific basis for future clinical research on IS. Methods: A comprehensive search was conducted across eight databases: PubMed, Embase, Web of Science, the Cochrane Library, China National Knowledge Infrastructure (CNKI), Wanfang Database, VIP Database, and the China Biomedical Literature Database (CBM). The search included all literature from the establishment of each library up to February 2025. Data analysis was performed using STATA 15.0 software. Results: A total of 15 studies involving 564 animals were included. The analysis showed that compared to the control group, SalA significantly reduced the infarct volume [ Conclusion: This meta-analysis demonstrates the therapeutic effects of SalA on IS. The results indicated that SalA significantly reduced the infarct area, improved neurological function scores, and alleviated brain edema. These effects were achieved through multiple mechanisms, including anti-inflammatory, antioxidative, antiapoptotic actions, along with blood-brain barrier (BBB) repair. SalA exhibited dose-dependent effects at different doses (especially 20 mg/kg) and administration methods. Further high-quality preclinical and clinical studies are needed for analysis. Systematic Review Registration: identifier INPLASY2025110038.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.